|MKEA -- France Stock|| |
EUR 2.90 0.025 0.87%
Chairman, Independent Director
Mr. Gilles Brisson was Chairman of the Board and Independent Director of Mauna Kea Technologies SA since March 5 2012. He is Member of the Company Audit Committee and Remuneration Committee. He has served in various roles during his 20year tenure at RhonePoulenc Rorer including Senior VicePresident of Corporationrationrate Development. He led Aventis French pharmaceutical business from 1999 to 2003 as President and Chief Executive Officer. Then he became Senior Vice President of Europe for Aventis and Sanofi aventis. Mr. Brisson was Chairman of the Supervisory Board of Innate Pharma since 2007 and of Ethypharm since 2009.
Age: 61 Chairman Since 2012
33 1 48 24 03 45 http://www.maunakeatech.com
The company has return on total asset (ROA)
of (35.99) %
which means that it has lost $35.99 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE)
of (123.6) %
meaning that it generated substantial loss on money invested by shareholders.
The company has accumulated 6.82 M in total debt with debt to equity ratio (D/E) of 83.4 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Mauna Kea Technologies SA has Current Ratio of 3.35 suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due.
Mauna Kea Technologies SA, a medical device company, develops and sells endomicroscopy and optical biopsy for the diagnosis and treatment of cancer and other diseases. The company was founded in 2000 and is headquartered in Paris, France. Mauna Kea operates under Medical Equipment classification in France and traded on Paris Stock Exchange.Mauna Kea Technologies SA (MKEA) is traded on Paris Stock Exchange in France. It is located in 9, rue d'Enghien and employs 81 people.
Mauna Kea Technologies Leadership Team
|Olivier Regnard, CEO|
|Bertrand Talhouet, Director|
|Eric Cohen, CFO, MBA|
|Gilles Brisson, Chairman|
|Alexandre Loiseau, CEO, Ph.D|
|Guillaume Bailliard, President, MBA|
|Christopher McFadden, Director, CFA|
|Francois Lacombe, Executive, Ph.D|
|Christopher Tihansky, President, MBA|
|JeanLuc Boulnois, Director, MBA|
|Bruno Villaret, President|
|Joseph DeVivo, Director|
|Christophe Bailleul, President, MBA|
|Agnes Rouffiac, Director|
|Veronique Dentan, Director|
|Sebastien Cadet, Director|
|Sacha Loiseau, CEO, Ph.D|
|Molly ONeill, Director|
|Pierre Forest, COO|
|John Soto, COO|
|Marie Meynadier, Director|
Stock Performance Indicators
Macroaxis portfolio users are evenly split in their trading attitude regarding investing in Mauna Kea Technologies SA. What is your trading attitude regarding investing in Mauna Kea Technologies SA? Are you bullish or bearish?
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations